Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $24.00.

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 15th. Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Needham & Company LLC increased their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Lake Street Capital upped their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $19.24 on Tuesday. Cellebrite DI has a 52 week low of $13.10 and a 52 week high of $26.30. The company has a market capitalization of $4.61 billion, a price-to-earnings ratio of 62.06, a PEG ratio of 3.28 and a beta of 1.29. The company has a 50-day simple moving average of $17.72 and a 200 day simple moving average of $16.66.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The company had revenue of $126.03 million during the quarter, compared to the consensus estimate of $122.98 million. During the same period in the prior year, the company earned $0.14 earnings per share. The firm’s revenue was up 17.9% compared to the same quarter last year. Sell-side analysts forecast that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Financial Management Professionals Inc. bought a new stake in Cellebrite DI during the third quarter worth $28,000. CWM LLC lifted its position in shares of Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after buying an additional 720 shares during the last quarter. Signaturefd LLC boosted its stake in Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after buying an additional 819 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in Cellebrite DI in the third quarter valued at about $38,000. Finally, PNC Financial Services Group Inc. grew its position in Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the last quarter. 45.88% of the stock is owned by institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.